Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis
PLOS One · 2026
DOI: 10.1371/journal.pone.0351183 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Gebremedhin B Gebretekle und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalizations among infants in Canada. New long-acting monoclonal antibodies (mAbs) and vaccines administered during pregnancy have expanded prevention options, yet the most cost-effective immunization program remains uncertain.
Methods
We updated a Canadian cost-utility model to evaluate seven seasonal RSV prevention strategies over one year (with a lifetime horizon for mortality impacts), from health system and societal perspectives. Strategies included RSVpreF vaccination in late pregnancy; targeted or universal infant mAb programs using nirsevimab or clesrovimab; and combination programs in which infants could receive protection from either RSVpreF or mAbs. Sequential incremental cost-effectiveness ratios (ICERs) were estimated in 2024 Canadian dollars per quality-adjusted life year (QALY), using a $50,000/QALY threshold. The primary analysis used immunization product list prices.
Findings
The most cost-effective strategy was a seasonal combination program: RSVpreF vaccination for pregnancies due during the RSV season, with mAb for infants at high risk (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- Communicable Disease Control, Public Health Ontario, Toronto, Ontario, Canada.
- Populations and Public Health, ICES, Toronto, Ontario, Canada.
- Section of Allergy and Clinical Immunology, Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada.
ORCID-Profile: Marie Lan, Jesse Papenburg, Winnie Siu, Ashleigh R Tuite
Zitieren
APA
Gebretekle, G. B., Lan, M., Xi, M., Ximenes, R., Buchan, S. A., Abrams, E. M., Andrew, M. K., Brousseau, N., Killikelly, A., Money, D., Papenburg, J., Rafferty, E., Robinson, J. L., Siu, W., Tunis, M., & Tuite, A. R. (2026). Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis. PLOS One. https://doi.org/10.1371/journal.pone.0351183
Vancouver
Gebretekle GB, Lan M, Xi M, Ximenes R, Buchan SA, Abrams EM, et al. Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis. PLOS One. 2026. doi:10.1371/journal.pone.0351183
BibTeX
@article{Gebretekle2026,
author = {Gebretekle, Gebremedhin B and Lan, Marie and Xi, Min and Ximenes, Raphael and Buchan, Sarah A and Abrams, Elissa M and Andrew, Melissa K and Brousseau, Nicholas and Killikelly, April and Money, Deborah and Papenburg, Jesse and Rafferty, Ellen and Robinson, Joan L and Siu, Winnie and Tunis, Matthew and Tuite, Ashleigh R},
title = {Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0351183}
}
EUVIMED